Health technology assessment (HTA) is the systematic evaluation of the properties and effects of a health technology, addressing the direct and intended effects of the technology as well as its indirect and unintended consequences. In many countries, it is a primary evaluation tool for making pricing and access decisions, providing a platform for understanding economic trade-offs.
HTA varies considerably across APAC and depends on country-specific factors, such as the proportion of public investment in health, political support, access to quality health information and technology infrastructure. With the rising cost of healthcare, HTA can be a useful tool to inform decision-making about universal healthcare (UHC ) and promote an equitable, efficient and high-quality health system.
HTA adoption has been slow in Asia due to disjointed research efforts; lack of awareness; and country-specific epidemiological, clinical and health economics data. It is also less important where government is not a principal payer. However, APAC countries have recently realized the necessity of providing value for money to patients while safeguarding accessibility of care. Several Asian countries are implementing HTA to measure the clinical and economic value of healthcare technologies. HTA offers the opportunity for governments, industry, providers and consumers to work together to ensure that medical technology is provided to the right patient, at the right time, at the right price.
Complete the form below to download the full article.
EVERSANA employs a team of over 6000 professionals across 40+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…